Amyotrophic lateral sclerosis

@article{Es2017AmyotrophicLS,
  title={Amyotrophic lateral sclerosis},
  author={Michael A. van Es and Orla Hardiman and Adriano Chi{\`o} and Ammar Al-Chalabi and R. Jeroen Pasterkamp and Jan Herman Veldink and Leonard H. Berg},
  journal={The Lancet},
  year={2017},
  volume={390},
  pages={2084-2098}
}
Amyotrophic lateral sclerosis is characterised by the progressive loss of motor neurons in the brain and spinal cord. This neurodegenerative syndrome shares pathobiological features with frontotemporal dementia and, indeed, many patients show features of both diseases. Many different genes and pathophysiological processes contribute to the disease, and it will be necessary to understand this heterogeneity to find effective treatments. In this Seminar, we discuss clinical and diagnostic… Expand
Genetics of amyotrophic lateral sclerosis: A review
TLDR
Since the first identification of a causative gene in the 1990s and with recent advances in genetics, more than twenty genes have now been linked to FALS, this increased number of genes led to a tremendous amount of research and contributed to a better understanding of the pathophysiology of this disorder. Expand
Family history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based case–control study
TLDR
This prospective case–control study aimed to describe the family aggregation of ND within the group of patients with ALS and to estimate the risk of ALS development in patients with a positive ND family history. Expand
Disease-modifying therapies in amyotrophic lateral sclerosis
TLDR
The pathological mechanisms relevant to ALS and current and future pharmacological and non-pharmacological trials, including gene and stem cells therapies, will be presented. Expand
Novel therapeutic targets for amyotrophic lateral sclerosis
TLDR
An overview of the contribution of different targets like mitochondrial dysfunction, glutamate transport and excitotoxicity, protein accumulation, Oxidative stress, neuromuscular junction, microglia, and other molecular targets in the pathogenesis of ALS are provided. Expand
Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder
TLDR
This review aims at identifying the most common psychiatric alterations related to ALS and its prognosis, looking at a common genetic background and shared structural brain pathology. Expand
Therapeutic news in ALS.
TLDR
This review presents the various treatment options currently being developed for ALS, from old drugs tested in a new indication to innovative drugs obtained via biotechnology or gene therapy, with an emphasis on the range of therapeutic approaches being explored. Expand
Sensory nerve disturbance in amyotrophic lateral sclerosis
TLDR
This review summarizes the discoveries related to sensory nerve disturbance in ALS, which may provide insightful information that will help to better diagnose and understand the disease. Expand
Astrocytes in Motor Neuron Diseases.
TLDR
A dissertation is substantiated by the findings that built awareness on the glial involvement and how the glia-neuronal interplay is perturbed, along with the appraisal of this new cellular site for possible therapeutic intervention. Expand
Cortical Circuit Dysfunction as a Potential Driver of Amyotrophic Lateral Sclerosis
TLDR
The possibility that initial cortical circuit dysfunction might act as the main driver of ALS onset and progression is discussed and the potential cellular and molecular origins of cortical hyperexcitability in ALS is evaluated. Expand
Inherited and Sporadic Amyotrophic Lateral Sclerosis and Fronto-Temporal Lobar Degenerations arising from Pathological Condensates of Phase Separating Proteins.
TLDR
This review uses the FUS, TDP-43 and A11 proteins as examples to illustrate how missense mutations and aberrant post-translational modifications of these proteins cause amyotrophic lateral sclerosis (ALS) and fronto-temporal lobar degeneration (FTLD). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 271 REFERENCES
Amyotrophic lateral sclerosis: moving towards a new classification system
TLDR
A new strategy is needed to combine the benefits of a systematic approach to classification with the rich and varied phenotypic descriptions used in clinical practice to avoid confusion between diagnosis and phenotype. Expand
State of play in amyotrophic lateral sclerosis genetics
TLDR
Current literature of the major genes underlying ALS, SOD1, TARDBP, FUS, OPTN, VCP, UBQLN2, C9ORF72 and PFN1 are summarized and how each new genetic discovery is broadening the phenotype associated with the clinical entity the authors know as ALS is outlined. Expand
A mutation in sigma‐1 receptor causes juvenile amyotrophic lateral sclerosis
TLDR
A consanguineous family segregating juvenile ALS in an autosomal recessive pattern is described and the genetic variant responsible for the disorder is described. Expand
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis
TLDR
The finding of seven missense mutations in 15 individuals, of whom four had familial ALS and 11 apparently 'sporadic' ALS, provides further evidence that variations in hypoxia-inducible genes have an important role in motor neuron degeneration. Expand
Gene discovery in amyotrophic lateral sclerosis: implications for clinical management
TLDR
It is observed that many gene variants associated with ALS have effect sizes between those of mutations that greatly increase risk and those of common variants that have a small effect on risk, and this observation is combined with insights from next-generation sequencing to explore the implications for genetic counselling. Expand
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
TLDR
Findings further corroborate that TDP-43 is involved in ALS pathogenesis and reports eight missense mutations in nine individuals—six from individuals with sporadic ALS and three from those with familial ALS (FALS)—and a concurring increase of a smaller T DP-43 product. Expand
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
TLDR
Ongoing research on the cellular pathways highlighted in this Review is predicted to open the door to new therapeutic interventions to slow disease progression in ALS. Expand
Mutations of optineurin in amyotrophic lateral sclerosis
TLDR
It is shown that there are mutations in the gene encoding optineurin (OPTN), earlier reported to be a causative gene of primary open-angle glaucoma (POAG), in patients with ALS and these findings strongly suggest that OPTN is involved in the pathogenesis of ALS. Expand
Projected increase in amyotrophic lateral sclerosis from 2015 to 2040
TLDR
The number of ALS cases across the globe will increase from 222,801 in 2015 to 376,674 in 2040, representing an increase of 69%. Expand
Amyotrophic lateral sclerosis.
TLDR
Tremendous progress has been made in the field of ALS based on recent neuropathological and genetic discoveries and the role of metabolism and nutrition in the pathogenesis of the disease is debated and may potentially serve as a future therapeutic target. Expand
...
1
2
3
4
5
...